Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04020263

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock (LevoHeartShock)

Sponsor: Pr Bruno LEVY

Interventions Levosimendan 2.5 MG/ML Injectable Solution Placebo

Updated 5 times since 2019 Last updated: Jul 31, 2025 Started: Jul 3, 2023 Primary completion: Feb 3, 2027 Completion: Jan 3, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04020263, this PHASE3 trial focuses on Cardiogenic Shock and remains actively recruiting participants. Sponsored by Pr Bruno LEVY, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE3

Status: Unknown → Recruiting
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Not Yet Recruiting → Unknown
Jan 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3
Aug 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pr Bruno LEVY

Data source: Central Hospital, Nancy, France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ars-Laquenexy, France , Avignon, France , Besançon, France , Bordeaux, France , Bron, France , Caen, France , Créteil, France , Dijon, France , La Tronche, France , Lille, France and 11 more locations